Amryt Pharma (NASDAQ: AMYT, AMYT.LON): Investor Relations Program

Amryt Pharma Plc is a global biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

LifeSci have worked extensively over the years to raise the Company’s visibility amongst investors and strategics, preparing the market for their positive data read out and ultimately leading to a successful acquisition.


  • Strengthen Amryt’s position as a global leader in rare and orphan diseases through strategic corporate communications following the acquisition of Chiasma Inc.
  • Target and maintain activity with prospective and current shareholders
  • Frame the investment thesis to highlight the profile and address risks
  • Raise overall global visibility with investors and strategics


This process yielded significant results when Amryt was acquired on January 8th, 2023. The total transaction value of up to US$1.48 Billion with upfront consideration representing a 107% premium to Amryt ADS’ closing price of $7.00USD on January 6th, 2023.



“We engaged with LifeSci Advisors over three years ago seeking expertise and guidance in US-based IR best practices in advance of our NASDAQ up-listing from the AIM exchange in London.  The team’s comprehensive onboarding method allowed them to understand and frame our story on a fundamental level. LSA worked in partnership with us to globalize and refine our communications capabilities through intense quarterly, M&A, and clinical data messaging workshops.   The deep relationships across LSA’s senior team facilitated key introductions and coordination of the bake-off among the investment bankers and research analysts that led to the syndicate formation and private placement in 2019.  LifeSci also systematically executed on investor targeting and hosting non-deal-road shows and well-attended KOL events with hundreds of investors of all types (institutional, HNW and Family Office) and analysts across the globe along the way to our ultimate proposed acquisition by Chiesi Pharma for $1.48B.”